Investors > News Releases
Jul 31, 2020
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
Pipeline
Jul 29, 2020
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
Pipeline
Jul 28, 2020
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
Pipeline
Jul 07, 2020
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
Products
Jul 01, 2020
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Products
Jun 25, 2020
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
Pipeline
Jun 15, 2020
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
Products
Jun 11, 2020
Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries
Pipeline
Jun 08, 2020
New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing
Products
Jun 04, 2020
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer
Pipeline
May 29, 2020
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients
Pipeline
May 26, 2020
Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
Pipeline
May 20, 2020
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
Pipeline
May 11, 2020
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
Pipeline
Apr 20, 2020
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder
Pipeline